Shrinking lung tumors before surgery: targeted drugs show promise for rare cancer type
NCT ID NCT07700836
First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study looks at whether giving targeted drugs called ROS1 inhibitors before surgery can help people with a rare form of lung cancer. The drugs, entrectinib or crizotinib, are designed to attack cancer cells with a specific genetic change. Researchers will check how much the tumor shrinks and how well surgery goes afterward.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ROS1 tyrosine kinase inhibitor drugs (entrectinib or crizotinib)
- What this could lead to
- If successful, this approach could make surgery more effective for people with this rare lung cancer, potentially improving long-term outcomes.
- What could go wrong
- This is a small, retrospective study with only 12 participants, so results may not apply to everyone. The drugs can cause side effects, and not all tumors may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
12 people
The number who actually took part.
- Started
-
Jul 2021
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with ROS1 fusion-positive locally advanced lung adenocarcinoma who had baseline M0 disease, received ROS1-TKI therapy before surgery, and underwent surgical resection at four tertiary hospitals in China.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 years or older. 2. Histologically confirmed lung adenocarcinoma. 3. ROS1 fusion positivity confirmed in tumor tissue at the DNA or RNA level. 4. M0 disease at baseline. 5. Receipt of targeted therapy before surgery. 6. Surgical resection performed after ROS1-TKI therapy. 7. Availability of comprehensive clinical, radiographic, treatment, surgical, pathological, and follow-up data. Exclusion Criteria: 1. Baseline M1 disease. 2. Receipt of radiotherapy or immunotherapy before ROS1-TKI therapy. 3. No surgical resection after ROS1-TKI therapy. 4. Lack of essential data for endpoint evaluation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROS1 fusion-positive lung adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital & Institute, Beijing, Beijing 100142
Beijing, Beijing Municipality, 100142, China